Publications and Presentations

Category:

Video - Brown - Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD, Clinical trial injection procedure after (dark orange) Betadine Ophthalmic Prep
Click to View
Presentation - Brown - Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD
Click to View
MacCumber et al - Suprachoroidal Administration of Small Molecule and Nanoparticle Suspensions: Pre-Clinical Results Correlate to Clinical Trial Outcomes
Click to View
Bhisitkul et al - Suprachoroidal CLS-AX (axitinib injectable suspension) as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
Click to View
Brown - Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
Click to View
Muya et al - Pharmacokinetics and Ocular Tolerability of Suprachoroidal CLS-AX (axitinib injectable suspension)
Click to View
Kaiser et al - Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
Click to View
Kurup - Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
Click to View

As a courtesy to our stakeholders, Clearside Biomedical, Inc. lists posters and presentations delivered on, or related to our programs at various medical meetings and in various publications. Some of these materials may be authored by individuals outside the Company with or without funding from Clearside. Please note that the studies, data, opinions, and other disclosures made by these individuals may not fully reflect the status of the Clearside programs. Clearside Biomedical does not by its reference above or distribution necessarily imply its endorsement of or concurrence with such information, conclusions, or recommendations.